# Nouscom

> Nouscom AG is a private, clinical-stage immuno-oncology company developing neoantigen-targeted
> cancer immunotherapies from a proprietary viral vector platform. Headquartered in Basel,
> Switzerland with research and manufacturing in Rome, Italy. Nouscom is a therapeutics developer,
> not a software vendor.

generated: 2026-08-26
method: generated
source: apis.yml + repo artifacts (API Evangelist enrichment pipeline). Provider serves no
llms.txt of its own — https://nouscom.com/llms.txt returns an HTTP 202 bot-challenge shell.

## There is no API

Nouscom publishes **no public API, developer portal, SDK, webhook surface or machine-readable API
contract**. If you are an agent looking for a Nouscom endpoint to call, there is not one. Probed
2026-08-26:

- No API host exists. `api.`, `dev.`, `developer.`, `docs.`, `portal.`, `app.`, `data.` and
  `status.nouscom.com` do not resolve.
- No OpenAPI, Swagger, GraphQL or AsyncAPI contract is published on any Nouscom host.
- No MCP server and no A2A agent card.
- The corporate site `nouscom.com` is a WordPress marketing and investor-relations site sitting
  behind a SiteGround bot challenge; every path answers HTTP 202 with a challenge shell.

## Company

- Founded: 2015, by Riccardo Cortese and Alfredo Nicosia
- Headquarters: Basel, Switzerland; research and manufacturing: Rome, Italy
- Sector: biotechnology / immuno-oncology / cancer immunotherapy
- Financing: oversubscribed EUR 67.5 million Series C, November 2023, co-led by Andera Partners,
  Bpifrance (InnoBio 2) and M Ventures, with 5AM Ventures, EQT Life Sciences, Versant Ventures,
  Angelini Ventures, Panakès Partners, Indaco Venture Partners, Revelation Partners and XGen
  Ventures participating.

## Programs

- **NOUS-209** — off-the-shelf viral-vectored immunotherapy encoding 209 shared frameshift
  neoantigens, in development for cancer interception in Lynch Syndrome carriers and, in
  combination with pembrolizumab, for dMMR/MSI metastatic colorectal cancer. Holds US FDA Fast
  Track Designation; Phase 1b/2 Lynch Syndrome results published in Nature Medicine.
- **NOUS-PEV** — personalized neoantigen immunotherapy for advanced solid tumors.

## Links

- Website: https://nouscom.com/
- Pipeline: https://nouscom.com/pipeline/
- About / team: https://nouscom.com/about/
- LinkedIn: https://www.linkedin.com/company/nouscom-ag/
- GitHub organization: https://github.com/Nouscom

## Public code

Nouscom's GitHub organization holds one public repository, and it is research code rather than an
API client or server:

- https://github.com/Nouscom/NOUS209LS-CRC-UC — R analysis scripts accompanying the NOUS-209
  Lynch Syndrome colorectal and urothelial cancer study.

## Disambiguation

Do not confuse Nouscom AG (nouscom.com, biotech) with:

- **noûscom** (nouscom.ch) — an unrelated Swiss company on a different origin.
- **Nous Research** (nousresearch.com) — an AI lab that does publish an inference API.
- **Nous AI** (nousai.com) — an unrelated company that publishes developer documentation.

These are distinct organizations. A search for "Nouscom API" returns results for the two Nous
companies; none of them belong to Nouscom AG.